

FOUNDERS.

At the University of Cambridge

Start 1.0


INVESTOR DEMO DAY 2024

23 May 2024

King's Place, London



UNIVERSITY OF
CAMBRIDGE



WELCOME

Welcome to our first ever Investor Demo Day – we hope you'll be inspired by the innovation and ingenuity you will see today.

Founders at the University of Cambridge is a new strategic initiative to bridge the gap between groundbreaking research and market success through capital investment, growth programming and curated access to an expert community.

Today marks the completion of Start 1.0, our first pre-seed accelerator. After 12 weeks of working round the clock to turn their research into life-changing solutions, our 11 founders have reached a new milestone of commercialising their life-long research. I hope important conversations start in this room because by working together, we can harness brilliant minds and shape the future of innovation.

Today Cambridge is a world-leading academic institution. Tomorrow our goal is to make it even more well known for its entrepreneurial pathways. Should you wish to be involved as a partner, sponsor, donor, or mentor, please do not hesitate to reach out. Thank you to our sponsors; KPMG, AstraZeneca and Hitachi, for supporting us on this journey so far. This is just the beginning!

My very best wishes to the amazing venture scientists who joined our first cohort. And thank you for coming – many of you have contributed to its success so far.



GERARD GRECH CBE

Managing Director,
Founders at the University of Cambridge

ACCELERATING BRILLIANCE

Founders at the University of Cambridge is a new strategic initiative building on University expertise and unparalleled advantages to bring technical and social innovation to life through new business creation; from solving climate change to finding cures to deadly diseases.

[FOUNDERS.CAM.AC.UK](https://founders.cam.ac.uk)

You can also follow our progress on LinkedIn



By supporting our founders we can fully unlock the innovation potential of Cambridge. We aspire to be the world leader in creating science-backed businesses. Founders at the University of Cambridge is exactly designed to accelerate this brilliance.



DR DIARMUID O'BRIEN

Pro-Vice-Chancellor for Innovation,
University of Cambridge

BREAKING THE MOULD

This small city an hour from the capital has generated, and continues to generate, achievements out of all proportion to its size.

Cambridge has evolved into a world class innovation ecosystem, a leader in globally significant research and intellectual property generation.

Often referred to as the 'Cambridge Phenomenon', 'Cambridge Cluster' or 'Silicon Fen', the Cambridge cluster brings together research excellence, deep and varied skills, flexible working space, investment and support services, all integrated through a connected ecosystem. Continuous innovation in each of these areas continues to offer new benefits, enabled by a supportive culture of open innovation.

Central to Cambridge's success is a unique and driven community of exceptional science, people, companies and partners, together tackling global challenges and changing lives.

Cambridge has been named the global number one Science and Technological Cluster (S&T) in the 2023 Global Innovation Index (GII).

The GI evaluates the top-level innovative capacity of countries and economies and identifies local concentrations of world-leading activity by intensity, in relation to its size. S&T clusters are established by analysing patent-filing activity and scientific article publication and documenting the geographical areas around the world with the highest density of inventors and scientific authors.

According to the Index, there have been 6,582 Patent Cooperation Treaty (PCT) patent applications and 37,136 scientific articles published per 1 million inhabitants over the past five years across the Cambridge Cluster.

DRIVING INNOVATION



Through Cambridge Enterprise, University research and expertise continues to deliver life-changing outcomes with world-changing impact.

Deeply embedded in the UK's leading innovation and entrepreneurial ecosystem, we have strong relationships with industry, investors and visionaries.

Cambridge Enterprise Ventures is the venture investment arm of the University of Cambridge. We support entrepreneurs and founders by investing University of Cambridge capital into high growth, high potential, high impact early-stage businesses.

CAMBRIDGE INNOVATION CAPITAL

As an established fund manager, we deliver equity investment and expert business support to world-changing Cambridge spin-outs.

Our expansive investor syndicate community includes Cambridge Innovation Capital, a fund established by Cambridge Enterprise in 2014, now a leading venture investor in the Cambridge ecosystem at Series A and beyond.

CAMBRIDGE IN NUMBERS

1st

in global rankings of no. of university alum founders who raised >£10M per inhabitant*

3rd

in global science cluster rankings*

23

unicorns, making it the science unicorn of Europe*

>£3.5bn

investment in University of Cambridge companies**

£23bn

annual economic impact to the UK economy from University of Cambridge -associated businesses***

6th

in global rankings for deep tech unicorn creation per inhabitant*

*Sources: Dealroom, 2023

**Cambridge Enterprise 2023

***London Economics 2023

BUILDING A FRONTIER TECH UNICORN FACTORY

Science and spin-outs: a start-up hub poised for the next decade of entrepreneurship and innovation.

In a recent benchmarking of global start-up ecosystems by Dealroom, Cambridge ranked third globally of science-based entrepreneurial hubs, alongside the Bay Area and Boston.

For the size of the city, Cambridge punches well above its weight, and now has a proven track record of building globally significant tech companies.

This year Arm became Europe's first 'centicorn' – a \$100bn tech company. Since Arm was founded, a further 11 Cambridge start-ups have reached unicorn status (\$1bn valuation), the most recent this year in Quantinuum and Wayve.

Unsurprisingly the University plays a pivotal role in the Cambridge tech ecosystem. Cambridge has the most university alumni who have raised at least \$10m in start-up funding, of any city benchmarked per capita.

The entrepreneurial flywheel is well and truly turning in Cambridge. Arm alone has already spawned scores of venture-backed start-ups founded by staff alumni, including Ledger and FiveAI. There are now a dozen local examples of how to build a unicorn. And the city has one of the most envied talent pools on the planet on tap.


As tech enters a new era of frontier technology, and looks to tackle some of the world's biggest problems through innovation, centres of science and research excellence will be best positioned to take the lead in the next decade of entrepreneurship.




YORAM WIJNGAARDE

Founder, Dealroom.co

TOP 10 EUROPEAN COUNTRIES WITH HIGHEST SPIN-OUT VALUE



TOP 10 SCIENCE HUBS



Source: Dealroom, 2023

A MATURE ECOSYSTEM

CUTECH

Cambridge University
Technology & Enterprise Club

JOHNIAN
ENTREPRENEURS' CLUB



Wolfson College
Cambridge



Cambridge
Femtech
Society



UNIVERSITY OF CAMBRIDGE
ALUMNI
CAMBRIDGE ENTREPRENEURS



TRINITY
HALL
ENTREPRENEURS
NETWORK



MITCAMBRIDGE



ENTREPRENEURSHIP LAB
KING'S COLLEGE
CAMBRIDGE



i-Teams

CAMBRIDGE GRAVITY

MedX
Cambridge



HOMERTON
CHANGEMAKERS



Lucy Cavendish College
University of Cambridge



Centre for
Global
Equality



CRoSS Ideas
Incubator

CAMSTART



Pembroke College
Cambridge



Venture
Creation
Weekends

Networking,
events & societies



Enterprise & innovation
programmes



Competitions



ENTREPRENEURIAL THINKING

ENTREPRE

The Cambridge tech ecosystem can be daunting to navigate so we are holding the Investor Demo Day in London to make it as frictionless as possible for London, UK and international investors to engage with this network and learn more about it.

Aspiring entrepreneurs can travel through the ecosystem, accessing the right programme or activity at each step, reaching the point where they have secured funding and are fully launched.


















Venture builders



Venture support

NEURAL ACTION

This graphic demonstrates just a few of the initiatives on offer for illustrative purposes.

FOUNDERS. Start 1.0

At the University of Cambridge



Each start-up is working on deep science to tackle difficult problems, from health and air quality to semiconductors. This programme will help them turn science into practical reality. We can't wait to see how they progress.



MARK LAZAR

Programme Director,
Founders at The
University of Cambridge



DR ANNE DOBRÉE

Director of Programming,
Founders at The
University of Cambridge

£4M

secured of dilutive and non-dilutive funding so far

WHAT THE PROGRAMME OFFERS

up to £200K

£40K up front and £160k after 12 weeks
based on achieving a set of milestones

50+

hours of intensive mentorship with your
handpicked Entrepreneur-in-Residence (EIR)


30+

additional mentors, partners and
investors offering dedicated support

12 weeks

of free ideaSpace membership and priority
access to Babraham Research Campus





AetoSense is on a mission to revolutionise control strategies around air quality with innovative ultrafine particle monitoring solutions.

Their focus is on the critical impact of airborne particles on health and energy efficiency.

Led by the founding team of particle detection experts, AetoSense has developed proprietary optical detection and flow conditioning technology which enables market-leading sensors' sensitivity at a competitive cost.

AetoSense technology is offered to air handling systems retailers, to provide healthier and more efficient working environments, with four pilot projects in the pipeline including with Dublin City. The sensors will be fundamental for building management under the 2027 regulation on air quality monitoring in the EU and UK, opening up a \$25bn market opportunity.

AETOSENSE.CO.UK
mollyhaugen@gmail.com

CO-FOUNDERS



Molly Haugen
CEO

Molly leads the research and development of low-cost and high-accuracy sensors for monitoring and improving indoor and outdoor air quality. With a PhD in Chemistry and over five years of postdoctoral experience at the University of Cambridge, she is adept at understanding and solving complex environmental challenges.



Shaamrit Balendra
CTO

Shaamrit is a PhD researcher at the Boies Research Group within the Department of Engineering. He previously worked on semi-conductor test/inspection instrument manufacture and asthma inhaler device modelling with Kindeva Drug Delivery (formerly 3M Healthcare, UK) and is interested in entrepreneurship and product development.

BIOTRYP THERAPEUTICS



By inhibiting biofilms, BioTryp's technology has the potential to revolutionise how we treat infection, providing a much-needed alternative to traditional antibiotic treatment.

Bacteria form biofilms as a protective shield against the immune system and antibiotics. Within biofilms, bacteria thrive, meaning that infections worsen, and treatments fail. With an initial focus on addressing the widespread issue of urinary tract infections (UTIs), BioTryp are developing novel small-molecule antibiofilms for bacterial infections. UTIs affect 400 million people annually, and biofilms in UTIs contribute to treatment failure and severe complications, making this a crucial challenge to solve.

The co-founders along with Scientific Director, Dr David Summers, have already gained traction with the award of the Hellings Prize as part of the Trinity Bradfield Prizes 2024.

BIOTRYP.COM
ash@biotryp.com

CO-FOUNDERS



Dr Ashraf Zaran

Technology co-inventor Ashraf holds a PhD in Biochemistry from the University of Cambridge, contributing over a decade of expertise in infectious disease research. As a Research Fellow at Cambridge's Department of Genetics, his background spans microbiology, bacterial genetics, antimicrobial resistance, and small molecule drug discovery.



Dr Jehangir Cama

Biophysicist Jehangir specialises in microfluidics, bacterial signalling, assay development and translational science. Currently a Fellow at Clare Hall, Cambridge, and a Research Associate at the Department of Materials Science and Metallurgy, he has worked on the socio-economic aspects of antimicrobial resistance, and on developing industry partnerships.

BRAVELY CULTURED



Using proprietary marine microbes, BravelyCultured is replacing animal, tropical oil, and petroleum-based products, starting with eco-friendly biosurfactants to replace their petroleum-derived counterparts.

James Dunce and his team are facing this pressing need for sustainable and eco-friendly alternatives in the surfactant market. Their technology reduces environmental pollution, avoids reliance on fossil fuels, minimises deforestation, and significantly lowers CO₂ emissions.

With demonstrated market interest and plans for expansion into various sectors, BravelyCultured is on a journey to disrupt the surfactant market sustainably.

FOUNDER




Dr James Dunce
CEO

James grew up by the coast and is passionate about the ocean. Diving in Central America and witnessing first hand the damage caused by chemical run off directly into the sea inspired James to found BravelyCultured.

A molecular biologist by training with a Biochemistry PhD from Newcastle University, he has most recently worked at the Department of Biochemistry, University of Cambridge, as a Herchel Smith Postdoctoral Fellow. He is now building the technical team at BravelyCultured, working towards creating a whole range of ocean-based natural ingredients to replace synthetic household product components.

james@bravelycultured.com



CAMBRIDGE VISION TECHNOLOGY



Cambridge Vision Technology has a secure and scalable system for the early detection of disease through a simple eye test, available at opticians.

It enables routine, non-invasive population level screening for a multitude of conditions, including Alzheimer's dementia, Parkinson's, and glaucoma, with the aim of global deployment.

Treatments for Alzheimer's disease, including the new monoclonal antibody treatments, slow the progression of the disease rather than reverse it. Scalable, early detection is key, so that treatments can begin before significant cognitive impairment manifests. Early detection is also key in the development of new treatments, that target this early phase, and in the modification of risk factors that contribute to up to 40% of dementias.

A contract to deliver a solution to the UK government is in place, with initial academic partner trials complete.

CAMBRIDGEVISIONTECHNOLOGY.COM
andrew@cambridgevion.tech

CO-FOUNDERS



Andrew Kadis
Founder

Andrew is a seasoned technology consultant specialising in connected medical-device IoT applications including wearable fitness trackers and the world's first COPD smart asthma inhaler. His portfolio includes managing R&D for Boston Scientific and GE Healthcare, and did his PhD in the Engineering Department in Cambridge.



James Wood
Founder

James founded his first company in 2006 after completing his degree in Physics at Oxford. It pioneered the first electronic clinical referral system used by the NHS. With an MBA from Columbia University, he has since acted as Head of Strategy and Machine Learning at PPAYA, an award winning platform that uses AI to help trade renewable energy.

MOLYON

Molyon

Molyon aims to be the leader in high-energy density batteries by enabling the lithium-sulfur battery.

Next generation batteries which are lighter and smaller are needed to support the net-zero transition.

A commercial lithium-sulfur battery based on Molyon's innovation provides superior performance at a lower cost; boosting the performance of weight-critical applications and enabling new modes of transport like electric aviation.

Supported by co-founders Dr Sai Shivareddy (Commercial Advisor) and Professor Manish Chhowalla (Scientific Officer), Molyon's long-life lithium-sulfur batteries deliver twice the energy density of current lithium-ion batteries on the market, at a fraction of the price due to more abundant materials.

MOLYON.COM
is448@cam.ac.uk

CO-FOUNDERS



Dr. Ismail Sami
CEO

Since completing his PhD in new materials for next generation batteries from Cambridge, Ismail is now a Research Fellow and Entrepreneurial Fellow at the Faraday Institution, Postdoctoral Researcher in Materials Science, Research Associate in King's College Cambridge, and winner of the Cambridge Enterprise Business Plan Competition 2023 for Molyon.



Zhuangnan Li
CTO

Zhuangnan obtained his PhD in Chemistry from UCL, before joining the University of Cambridge as a Postdoctoral Researcher. His deep expertise is in developing novel materials for new battery technologies unlocked the innovation behind Molyon. He is a Herchel Smith Postdoctoral Fellow and Fellow at King's College.



NANOMATION



Nanomation is a semiconductor software company automating the use of nanomaterials within industry for the development of novel computing applications.

Using semiconducting nanomaterials makes electronics faster, more powerful, and more efficient. They can add sensing, quantum and photonic functionalities to chips, which are not possible using traditional silicon alone. However, manufacturing with nanomaterials is currently impossible at commercial scale because they require manual integration that is too costly for industry.

Nanomation's fully automated software solution means there is no need for manual integration. It provides highly accurate feature identification at the nanoscale, material characterisation, and automated circuit layout design, enabling commercial development of advanced electronics applications.

NANOMATION.TECH

teja.potocnik@nanomation.tech

CO-FOUNDERS



Dr Teja Potocnik
CEO

Teja is CEO and co-founder of Nanomation, which commercialises her PhD research from the University of Cambridge. She also holds a BSc in Material Science and Engineering from the University of Manchester.



Charlotte Esler
COO

Previously a VP in the Equities Department of Mizuho Financial Group, Charlotte holds an MBA from the University of Cambridge and a Master in Public Policy from Harvard University.



Dr Jack Alexander-Webber
CSO

Jack is a Royal Society Dorothy Hodgkin Research Fellow at the University of Cambridge. He holds a DPhil in Condensed Matter Physics from University of Oxford.



ORBIT



Orbit is revolutionising mental health by making it as clear and actionable as physical health, using groundbreaking non-invasive neurotechnology.

Despite continuous and rapid technological advancements, mental health and wellbeing has been left behind and is still not well understood.

By collecting unprecedented amounts of functional brain data, Orbit aims to illuminate (literally) how our brain works.

With a powerhouse team skilled in software, consumer hardware, and neuroscience, Orbit is crafting a state-of-the-art wearable. Its mission is to decode and enhance cognition by creating the first-ever foundational model of the brain in the real world, using advanced, non-invasive techniques.

FOUNDER



Akshat Sharma
CEO

Akii undertook his Master's in the Neuro-Optics Lab and built the first Brain-Computer-Interface using a non-invasive imaging modality (High Density Diffuse Optical Tomography). After winning prizes at several international conferences, he focused his efforts into empowering people outside the lab with the wonders of neurotechnology, and Orbit was born!

TRYORBIT.CO

akshat1.sharma@outlook.com



PROTONERA



Protonera aims to realise the scalability of a novel plastic upcycling technology to transform waste plastics into green hydrogen and other value-added commodities.

There are three major bottlenecks that plague plastic recycling: the inability to process low-grade waste feedstocks, high operational costs from sorting contaminated feedstocks, and poor revenue from low-value products.

With a focus on addressing critical challenges within a substantial plastic recycling market, the team is creating a solution that degrades low-grade waste plastics that are not currently recycled and realises high profitability from product revenue.

Led by Dr Jack Chengzhi Guo and Professor Erwin Reisner, they are also supported by Technology Advisor, Professor Florian Hollfelder.

PROTONERA.COM
jcguo@protonera.com

CO-FOUNDERS



Dr Jack Chengzhi Guo

After repeatedly telling his grandfather to stop picking up waste plastic bottles, Jack grew tired of this futile endeavour and decided to tackle plastic pollution altogether. During his PhD, he developed biocatalysts to break down petrol-derived polymers. He is now moving forward with commercialising a waste-to-value technology at Protonera.



Professor Erwin Reisner

Erwin is the Professor of Energy and Sustainability in the Department of Chemistry and a Fellow of St. John's College. He is an expert in renewable energy and sustainable chemistry, in particular sunlight-powered production of sustainable fuels and platform chemicals. He was awarded the 2023 Hughes Medal by the Royal Society, among other accolades.



VOLTQUANT



VOLTQUANT is a pioneering company that offers the world's first search engine for grid connections, primarily aimed at empowering project developers to seamlessly connect to the grid using a machine-learning-enabled platform.

The company's focus on the UK's advanced smart energy grid aims to tackle challenges associated with the transition to net-zero energy infrastructure, particularly the instability of renewable sources.

By providing solutions for stakeholders and navigating the complexities of the UK's smart grid, VOLTQUANT aims to contribute to global efforts in sustainable energy development and assist other countries facing similar challenges in achieving their net-zero goals.

CO-FOUNDERS



Nikita Dabizha
CEO

Nikita holds a Master's in Industrial Systems, Manufacturing and Management from the Institute for Manufacturing. The idea for VOLTQUANT came to him whilst he was working at an investment firm and he saw the real-life impacts that grid issues were having on renewable energy projects.



George Kolokotronis
CTO

George holds a Master's in Industrial Systems, Manufacturing and Management at the Institute of Manufacturing (IfM), within the Department of Engineering. He previously worked within Amazon Web Services, helping scale companies with cutting edge technology cost-efficiently.

VOLTQUANT.COM
nikita@voltquant.com



WILLIAM OAK DIAGNOSTICS



William Oak Diagnostics is developing a point-of-care test for micronutrient deficiencies for maternal, infant and child health, bringing a better standard of health around the world.

The micronutrient test has significant social impact, improving healthcare access and enabling early intervention. Focused on maternal and child health, it addresses issues like iron deficiency anaemia and other deficiencies that can have serious health implications, offering quick results and reducing the costs of hospital-based tests.

Their innovative approach will simplify blood collection, providing clear results through a phone app, having the potential to personalise nutritional health monitoring for individuals. Ultimately, it will empower individuals to foster healthier lives and prevent the serious consequences of vitamin deficiency in vulnerable social groups.

WILLIAMOAKDIAGNOSTICS.COM
alex@williamoakdiagnostics.com

CO-FOUNDERS



Dr Alexander Patto

Alex is CEO and co-founder of William Oak Diagnostics. He holds a PhD in Genetics from the University of Cambridge and is a Royal Academy of Engineering Enterprise Fellow, as well as a Borysiewicz Biomedical Fellow. Previously Alex was CEO of social enterprise WaterScope, a University of Cambridge spin-out.



Dr Tim Dwyer

A biochemist with over 25 years' experience in designing, developing and commercialising novel medical device platform technologies, Tim has held significant scientific and leadership roles including at Oxford Immunotec, Vivacta, Novartis, AgPlus Diagnostics and as CTO of Mologic (now GADx). A Fellow of the Royal Society of Biology, Tim also holds an MBA.



XTERNA



Xterna is harnessing nature's barcodes for precision drug targeting, to revolutionise solid tumour cancer therapies.

Drugs widely diffuse in the body, resulting in ineffective doses at diseased organs and toxic accumulation in non-target tissues.

For successful targeting, drugs must be combined with modalities that home them to specific cells. While the crowd focuses on classical surface proteins, Xterna focuses on nature's newly identified surface barcode.

As a beachhead application, the team are demonstrating the capabilities of the Xterna platform with a lead asset, a solid tumour specific immune engager, before expanding into further cell and cargo classes.

XTERNA.UK
jess@xterna.uk

CO-FOUNDERS




Dr Jessica Corry
CEO

Jess is CEO and co-founder of Xterna. A cancer biologist by background, Jess was previously a PhD student at Caius College in the Department of Biochemistry and worked with AstraZeneca. Jess is currently a Postdoctoral Fellow at the Francis Crick Institute.



Dr Christopher Wan
CSO

Chris is CSO and co-founder of Xterna. Originally from Hong Kong, Chris read Natural Sciences at Magdalene College and subsequently completed a PhD in synthetic biology and alternative nucleic acid biology at the Laboratory of Molecular Biology with Dr Phil Holliger. Chris is also a Postdoctoral Fellow at the Francis Crick Institute.



THANK YOU

to our expert community of over 150 people, in 10 countries, who collectively have founded 100 companies and backed hundreds of ventures worth £15bn so far. Their experience is invaluable.

AASHIMA ARORA Partner, LocalGlobe

ALEKSANDRA PEDRASZEWSKA Co-founder, VividQ

AMELIA ARMOUR Partner, Amadeus

ANDY PHILLIPPS Co-founder, Booking.com

ARIANNA HUFFINGTON Founder & CEO, Thrive

BYRONIE EPSTEIN Co-founder & COO, Deep Medical Therapeutics

CHAD EDWARDS VP Strategic Partnerships, Quantum

CARMEN PALACIOS-BERRAQUERO CEO, Nu Quantum

CATHERINE BRESLIN Founder, Kingfisher Labs

CATHERINE ELTON CEO, Qkine

CLARE JONES Chief Commercial Officer, what3words

CHARLOTTE SALLEY Senior Content Manager, Morning Brew

CHECK WARNER Partner, Ada Ventures

CHRIS MAIRS (CBE) Director, Raspberry Pi

CHRIS MORTON Founder, Lyst

DAPO TOMORI Venture Advisor, Iaso Ventures

DEBU PURKAYASTHA Managing Partner, 3rd Eye

ED NEWTON-REX Scout, Andreessen Horowitz

GAYNOR FRYERS Coach & Mentor,

Cambridge Judge Business School

GIORGIA LONGOBARDI Founder & CEO,

Cambridge GaN Devices Limited

HAILEY EUSTACE CEO, Complicated

HAZEL MOORE (OBE) Chairman and co-founder, First Capital

INÈS HOLZBAUR Founder & Managing Partner, AmorChem

IRIS GOOD Advisor, Martlet Capital

ISABELLA CONVERTINI Strategic Partnerships Consultant

ITXASO ARAQUE BARRIUSO Head of Startup Segment, Amazon

JAMES COLE Chief Innovation Officer, Cambridge Institute for Sustainability Leadership (CISL)

JAMES THOMAS Angel Investor

JANE DANCER Non Exec Chair, PharmEnable

JIAHAO HUANG CoFounder and CFO, Nuclera

JOE WHITE (MBE) His Majesty's Tech Envoy to the United States, Foreign, Commonwealth and Development Office

JOHN CASSIDY Partner, Kindred Capital VC

JOHN RAINEY Operating Partner (Product), Gallos Technologies

JON BRADFORD Managing Partner, Dynamo Ventures

JULIA HAWKINS General Partner, LocalGlobe

JURGEN VAN GAELE European CTO, Stripe

KATY WIGDHAL CEO, Speechmatics

KELLY RICHDALE Advisor, SandboxAQ & World Economic Forum

KERRY BALDWIN Co-founder & Managing Partner, IQ Capital

KEVIN MCDONNELL CEO & Founder, Datalla Group

KEVIN WITHANE Founder, DiversityX

KRIS NAUDTS Chairman, Culture Trip

LAUREN TACK Investor, Invigorate Ventures

LUDO CHAPMAN Chair, Zetta Genomics

MALCOLM BURWELL Board Director,

UltraConductive Copper Company Inc

MAX AZAHAM Senior Director, Gartner

MAXIMILIAN BOCK Co-founder & COO, Blang Blang

MEHRYAR HAMID Head of E-Commerce CEE & MEA, Microsoft

MIRUNA-IOANA GIRTU Partner, SyndicateRoom

NICK RIMMER Director, Telegraph Materials

NICKY DIBBEN Marketing Consultant, Invention Marketing

NIGEL PITCHFORD Partner, Downing

NIKHIL SHAH Founder, MixCloud

NIKO BONATOS Managing Director, General Catalyst

NIGEL TOON Founder & CEO, Graphcore

NIMA MEHDIAN Strategy & Business Operations, Go Cardless

NIRMESH PATEL Principle, The Venture Collective

OLIVER LO VP Marketing, Surge, Sequoia Capital

PADDY STOBBS Founder, Stackfix

PAM GARSIDE Chair, Cambridge Angels

PAUL BAILEY Managing Director, Martlet Capital

PAUL FORSTER Co-founder, Indeed.com

PETE HUTTON Chairman, Xampla

PRIYA GUHA (MBE) Venture Partner, Merian Ventures

RAJ GANATRA Strategy & Operations, YouTube / Google

RAHUL VOHRA Founder, Superhuman

RAOUL-GABRIEL URMA Executive Chairman, Cambridge Spark

REBECCA SIMMONS COO, Riverlane

RICHARD GREEN Chairman, Nyobolt

ROB MOFFAT Partner, Balderton Capital

ROSEMARY FRANCIS Chief Scientist, Altair

SHAILENDRA VYAKARNAM Venture Partner, Embryo Ventures

SIMON HOMBERSLEY Founder, Puntios

SOPHIE ADELMAN Co-founder & CEO, One

STAN BOLAND CEO, FiveAI

STEPHANIE RICHARDS Global Innovation Policy Specialist, 500 Global

SUHAIR KHAN Founder, OpenEnded

SURANGA CHANDRATILLAKE General Partner, Balderton Capital

TESSA CLARKE Co-founder & CEO, Olio

TING ZHANG Founder & CEO, Crayfish.io

TOM ADEYOOLA Chair, Spoke

TOM WILSON Partner, Seedcamp

VISHAL CHATRATH Founder & CEO, QuantrolOx

To our Entrepreneurs-in-Residence

ALEKSANDRA PEDRASZEWSKA Co-Founder at VividQ, Fractional COO and Advisor to IP-driven ventures

DAVID LLEWELLYN SIMMONS Over 35 years of experience in academic and industrial biomedical research sectors

IRIS GOOD Chair of Imperial College Seed Fund, Cambridge Enterprise investment committee member

JAMAL BUTT CEO Medadvisor UK, Non Executive Director Croydon NHS Hospital, Chairman Croydon Health Charity

ANTHONY FINBOW CEO at Eagle Genomics

JONATHAN BRADFORD Managing Partner at Dynamo Ventures

PETE HUTTON Chairman at Agile Analog, Cambridge GAN Devices and Xampla

RICHARD GREEN Chairman/Non Executive Director/ Advisor/Investor of a number of early/growth stage businesses

To our mentors

CHRISTINA NESHEVA

SIMON HOMBERSLEY

AMELIA ARMOUR

ALEKS PEDRASZEWSKA

GEORGE NEVILLE-JONES

JAMES THOMAS

MARCO DELISE

AGATA NOWICKA

PAUL BAILEY

JOHN CASSIDY

PHILIP WINTER

ANTHONY FINBOW

TOM MASON

NAT EDINGTON

YAN ZHANG

DOMINIC PRIDE

KATE ROWLEY

KEVIN MCDONNELL

BRENDAN GILL

LAUREN TACK (STEWART)

DAVID BUXTON

GRAHAM SNUDDEN

OMAR DANIEL

LUDO CHAPMAN

GAYNOR FRYERS

STEVE CHURCHHOUSE

SIMON HAY

MARK ROGERS

RICHARD BRAY

STEVE MARSH

MIKE HERD

ANDY PHILLIPS

CHRIS SMART

CHRIS MAIRS

DAVID SHEPPARD

LAURENCE GARRET

and to our team.

ANCA BELU Global Community Lead

CONNOR FARRELL Programme Associate

THEA GOODLUCK Community Expert

ALENA PROTASOVA Programme Associate

WINNY SANCHITA Programme Associate

PARTNERS

We believe in the strength of collaboration and the power of community. Our success is deeply intertwined with the support and expertise of our esteemed partners, who share our commitment to nurturing innovation and empowering visionary founders.

We hugely thank them for their support throughout.

Our sponsor partners



Our community partners



And our investment partner.



Delivered by



The ability of the UK to exploit the potential of research carried out in university labs – not just in Cambridge but around the country as a whole – has never been more important.